The Food and Drug Administration Friday granted an emergency use authorization for Johnson & Johnson’s single-dose COVID-19 vaccine. Following the EUA’s issuance, the Centers for Disease Control and Prevention accepted the recommendation of its own Advisory Committee on Immunization Practices to give its own approval.

The vaccine is approved for patients 18 years old and older and began shipping this morning; Johnson & Johnson expects to supply 20 million doses by the end of March.

Related News Articles

Headline
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2…
Headline
The Food and Drug Administration and Centers for Disease Control and Prevention today jointly recommended a pause in the use of Johnson & Johnson’s…
Blog
Our doctors, nurses and clinical staff have responded to the COVID-19 pandemic with dedication and bravery. Yet, the pandemic’s longevity, as well as COVID-19’…
Headline
The Centers for Medicare & Medicaid Services will no longer waive certain requirements for long-term care and skilled nursing facilities beginning May 9 or…
Chairperson's File
One legacy of our response to COVID-19 surely will be how it has accelerated the adoption of virtual care. It is one of the more encouraging developments…
Headline
Pfizer today said it is seeking an amended emergency use authorization for its COVID-19 vaccine, requesting that the Food and Drug Administration allow…